ASTRAZENECA PHARMA INDIA LTD. - Launch Of Palivizumab (Synagis)

We refer to our earlier communication dated September 30, 2023, intimating the receipt of Import and Market Permission in Form CT-20 from Drugs Controller General of India for Palivizumab (Synagis) solution for injection 100mg/ml (r-DNA origin) (50mg/0.5mL & 100 mg/mL) presentations in single dose vials administered through intramuscular route). With regard to the same, we wish to further update that the Company will launch Palivizumab (Synagis) in October 2024 in India.